Although a Phase 2 trial was planned to administer metformin pre-surgery and measure changes in tumor pS6 and other AMPK/mTOR biomarkers, it was withdrawn before completion possibly due to slow accrual [91]. This evidence concerns the gene MTOR and neoplasm.